Compare iShares International Treasury Bond ETF (IGOV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Novartis AG — how do they compare? iShares International Treasury Bond ETF trades at $39.74 (market cap $1.30B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 206.6× iShares International Treasury Bond ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Novartis AG for 82 Days on average.
| IGOV | NVS | |
|---|---|---|
Market Cap | $1.30B | $268.57B |
Volume | 693,740 | 1,532,573 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $168.62 |
52-Week Low | $39.65 | $121.80 |
Typical Hold Time | 92 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.73, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. Key financial ratios such as P/E and P/S are not available in the provided data. Recent news highlights rising global bond yields, which may impact interest-rate-sensitive assets.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from higher yields. Investment opportunities hinge on undisclosed fundamentals, while risks include market volatility and interest rate sensitivity. Investors should await clearer financial disclosures for a full assessment.
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
